Biosimilars Company

Sandoz is a global leader in generic pharmaceuticals and biosimilars, having pioneered the first biosimilar approval in the United States and Europe. The company focuses on developing and commercializing high-quality, affordable follow-on versions of complex biologic medicines and a broad portfolio of generic small-molecule drugs. Sandoz operates across several key therapeutic areas, including immunology, oncology, endocrinology, and underserved disease states. Following its spin-off from Novartis in 2023, Sandoz functions as an independent, publicly traded entity dedicated to increasing patient access to critical medicines worldwide.